

1. [AYUSH drugs to get trial guidelines](#) –**The Hindu**

To bring research on Ayurvedic drugs and formulations closer to practices in Western medicine, the Indian Council of Medical Research has released a set of guidelines concerning standards that must be adhered to in testing medicines from AYUSH (Ayurveda, Yoga, Unani, Siddha and Homeopathy) schools.

If a mix of medicinal systems are involved, then there ought to be experts from each of those fields supervising trials and if a product deriving from traditional knowledge were to be commercialised, the “legitimate rights/share of the tribe or community from which the knowledge was gathered should be taken care of appropriately while applying for Intellectual Property Rights and patents for the product”, the guidelines say.

1. [AYUSH drugs to get trial guidelines](#) – The Hindu
2. [Programme launched to integrate Ayurveda with NPCDCS](#) – Business Standard
3. [1.3% of GDP spent on healthcare in 2015-16 by Centre and states](#) – The Economic Times
4. [Breakthrough cancer drugs all set for India launch](#) – The Economic Times
5. [Sun Pharma gets USFDA nod for generic diabetes treatment drug](#) - The Hindu Business Line
6. [Kerala to get a healthy act with clinical precision](#) – The New Indian Express
7. [5.2 million medical errors are happening in India annually: Dr Girdhar J. Gyani](#) – ETHealthworld.com

2. [Programme launched to integrate Ayurveda with NPCDCS](#) – Business Standard

The government through its research organisations, including CCRAS has launched a programme to integrate Ayurveda with the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), Ayush Minister Shripad Naik today said. In a written response to a question in Rajya Sabha, Naik said the Government has set-up the Central Council for Research in Ayurvedic Sciences (CCRAS) an autonomous organisation, with the mandate to undertake research in ayurvedic system of medicines and practice.

Also appeared on-

[Programme launched to integrate Ayurveda with NPCDCS](#) – Indiatoday.com

3. [1.3% of GDP spent on healthcare in 2015-16 by Centre and states](#) – The Economic Times

The expenditure on healthcare in last fiscal by the Centre and state governments was 1.3 per cent of the GDP; the Rajya Sabha was informed today. As per the Economic Survey 2015-2016, the expenditure by government (Central and state governments combined) on health as percentage of GDP was 1.3 per cent, Minister of State for Health and Family Welfare, Anupriya Patel said in a written reply to a question in the Upper House. She said as per World Health Statistics 2015, India's per capita government expenditure on health in 2012 was USD 60, while the US spent USD 4,153.

4. [Breakthrough cancer drugs all set for India launch](#) – The Economic Times

Cancer patients in India are set to gain faster access to two of the world's best known new generation drugs - Keytruda from US based Merck and Bristol Myer Squibb's Opdivo - both used to treat melanoma, a form of malignant skin cancer and a life-threatening lung cancer. According to a top health ministry official, while Keytruda has recently been granted approval by the Drug Controller General of India in line with recommendations of expert oncologists and a powerful apex committee, Opdivo has secured waiver from clinical trials a few months ago, paving the way for its marketing authorization.

5. [Sun Pharma gets USFDA nod for generic diabetes treatment drug](#) - The Hindu Business Line

Sun Pharmaceutical Industries has received final nod from the US health regulator for its generic Metformin Hydrochloride extended release tablets used for the treatment of diabetes. The company plans to launch them in the next few weeks in the American market. One of the subsidiaries of the company “has received final approval from United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic version of Glumetza Metformin Hydrochloride extended release tablets,” Sun Pharma said in a BSE filing.

Also appeared in-

[Sun Pharma slips despite USFDA nod for generic diabetes drug](#) – The Economic Times

6. [Kerala to get a healthy act with clinical precision](#) – The New Indian Express

In response to the strong call to ensure accountability of private healthcare and regulation, the State Government is set to implement the Kerala Clinical Establishment Act. The move is widely appreciated owing to a host of benefits ranging from affordable rates to quality service. But, the private hospitals, which boast of 70 per cent of state’s health sector, have raised strong concerns, which they want to be immediately addressed. Private hospital managements claim that some of the clauses of the Act are not appropriate for Kerala. Patients here widely rely on medium private hospitals, where services are affordable. The Act stipulates to appoint only qualified hands as per the standards of the State Health Department.

7. [5.2 million medical errors are happening in India annually: Dr Girdhar J. Gyani](#) – ETHealthworld.com

Dr Girdhar J. Gyani, Director General, Association of Healthcare Providers (India), New Delhi, talks to ETHealthworld about the issues and challenges that exist in the current Indian healthcare system.

Healthcare has still not come to that stage where they invest money. Thanks to the private sector starting from 1980 onwards, now we are able to have 5% investment of GDP in healthcare- 1% from government and 4% from the private healthcare.